Document Detail

Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels.
MedLine Citation:
PMID:  12207145     Owner:  NLM     Status:  MEDLINE    
In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. After completing 6 weeks of medication with either amisulpride or flupenthixol, the patients entered a long-term maintenance treatment with amisulpride 200-600 mg/day or flupenthixol 5-15 mg/day for a maximum of 12 months with a subsequent drug-free follow-up until month 15. Eighteen initially included patients were still participating in the study at month 6. In the flupenthixol group, only 1 patient treated reached month 12, and none of the patients reached month 15. For the amisulpride treatment group, months 12 and 15 were completed by 9 and 6 patients, respectively. After 1, 3, 6, and 12 months of treatment, and finally 3 months after cessation of treatment, the basal and thyrotropin-releasing hormone-stimulated secretions of prolactin were investigated. The prolactin plasma levels were elevated in both treatment groups during the course of maintenance treatment with a maximum effect at month 1. Flupenthixol treatment initially raised the prolactin levels about two- or threefold, and a subsequent decline during months 3 and 6 occurred. However, only the changes for month 1 reached the level of a statistical trend. The prolactin secretion was initially increased over tenfold by amisulpride. The prolactin levels at months 1, 3, 6, and 12 were significantly elevated as compared with the baseline values. A continuous decline of prolactin levels in both treatment groups occurred over the course of the next months. The prolactin response after the thyrotropin-releasing hormone challenge was not significantly changed over the long-term course. Notably, in the amisulpride group, 3 months after cessation of treatment at month 12, the elevated levels of prolactin returned to baseline at month 15. In summary, amisulpride demonstrated more pronounced effects than flupenthixol on the prolactin levels. However, the findings indicate also that treatment with amisulpride at clinically effective doses can be achieved at significantly lower prolactin levels during the long-term maintenance phase than during the prior acute phase.
R Schlösser; G Gründer; I Anghelescu; A Hillert; S Ewald-Gründer; C Hiemke; O Benkert
Related Documents :
18478155 - Treatment of central precocious puberty by gnrh analogs: long-term outcome in men.
23142445 - Inpatient mortality after primary total hip arthroplasty: analysis from the national in...
10619985 - Growth response to rhigf-i 80 microg/kg twice daily in children with growth hormone ins...
15562375 - Human chorionic gonadotropin therapy in adolescent boys with constitutional delayed pub...
4014545 - Acute pancreatitis in algeria. report of 221 cases.
912975 - Loosening associated with g.s.b. hinge total elbow replacement in patients with rheumat...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuropsychobiology     Volume:  46     ISSN:  0302-282X     ISO Abbreviation:  Neuropsychobiology     Publication Date:  2002  
Date Detail:
Created Date:  2002-09-03     Completed Date:  2002-10-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7512895     Medline TA:  Neuropsychobiology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  33-40     Citation Subset:  IM    
Copyright Information:
Copyright 2002 S. Karger AG, Basel
Department of Psychiatry, University of Mainz, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / administration & dosage,  pharmacology*
Drug Administration Schedule
Flupenthixol / pharmacology
Middle Aged
Prolactin / blood*,  drug effects*
Schizophrenia / blood*,  drug therapy*
Sulpiride / administration & dosage,  analogs & derivatives*,  pharmacology*
Thyrotropin-Releasing Hormone / blood
Time Factors
Reg. No./Substance:
0/Antipsychotic Agents; 15676-16-1/Sulpiride; 24305-27-9/Thyrotropin-Releasing Hormone; 2709-56-0/Flupenthixol; 53583-79-2/sultopride; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disor...
Next Document:  Impact of cortisol on emotions under stress and nonstress conditions: a pharmacopsychological approa...